Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fisher & Paykel Healthcare Corporation Limited (FSPKF) and Arctur...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARCT	$7.41	+21.88%	1.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARCT	$7.41	+21.9%	1.46M
3
4
5
6

ARCT

ARCT

Get Arcturus Therapeutics Holdings Inc. Data in Excel

Get Arcturus Therapeutics Holdings Inc. Data in Excel